• Gri Bio posted a GAAP net loss of USD 1.64 million for the quarter ended June 30, 2026, narrowing from USD 2.89 million.
• Operating loss narrowed to USD 1.65 million from USD 2.9 million as operating expenses fell to USD 1.65 million from USD 2.9 million.
• R&D spending dropped to USD 407,000 from USD 1.88 million due to completion of the Phase 2a GRI-0621 trial.
• G&A costs rose to USD 1.24 million from USD 1.02 million on higher public company expenses.
• Cash totaled USD 10.9 million at June 30, 2026; cash runway projected through Q2 2027 under the current operating plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001824293-26-000055), on August 14, 2026, and is solely responsible for the information contained therein.